NCT05223920CompletedPhase 2
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
Source: ClinicalTrials.gov · Last updated 22 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- First submitted
- 31 Aug 2021
- Start date
- 15 Dec 2021
- Primary completion date
- 22 Aug 2024
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05223920
- EudraCT number
- 2021-002452-37
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 81
- From 15 Dec 2021 to the primary completion date, 22 Aug 2024
- 19 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A history of non-compliance in a prior bomedemstat study (excluding dose suspensions that were medically warranted).
- Current use of a prohibited medication (e.g., romiplostim).
Other illness
- Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's safety, ability to give informed consent, or comply with the trial protocol.
Other
- Ongoing participation in another investigational study (except observational studies).
- Is pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
- Women of childbearing potential (WOCBP) and fertile men unwilling to agree to use an approved method of contraception from time of enrollment until 14 days after last bomedemstat dose.
Who the study is looking for
- Has completed at least one Treatment Period (TP) in a prior bomedemstat Myeloproliferative Neoplasms (MPN) protocol (such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003) (NCT04254978).
- In the estimation of the Investigator, the risk-benefit favors continued dosing with bomedemstat.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (19)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Adelaide Hospital Coordinator of this site? Confirm its status | Adelaide | Australia | Unknown status |
| Royal Prince Alfred Hospital Coordinator of this site? Confirm its status | Camperdown | Australia | Unknown status |
| Royal North Shore Hospital Coordinator of this site? Confirm its status | Saint Leonards | Australia | Unknown status |
| Gold Coast Hospital and Health Service Coordinator of this site? Confirm its status | Southport | Australia | Unknown status |
| Universittsklinikum Essen Coordinator of this site? Confirm its status | Essen | Germany | Unknown status |
| University College London Hospitals NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Guy's and Saint Thomas' NHS Foundation Trus Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Queen Mary Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
| Azienda Ospedaliera SS. Antonio Coordinator of this site? Confirm its status | Alessandria | Italy | Unknown status |
| Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM) Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
| Azienda Ospedaliero Universitaria di Bologna Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
| Ospedale di Circolo-a Fondazione Macchi Coordinator of this site? Confirm its status | Varese | Italy | Unknown status |
| Middlemore Clinical Trials Coordinator of this site? Confirm its status | Papatoetoe | New Zealand | Unknown status |
| Waitemata District Health Board Coordinator of this site? Confirm its status | Takapuna | New Zealand | Unknown status |
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| Cleveland Clinic Foundation Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
| University of Miami Leonard M. Miller Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| UMPC Hillman Cancer Center Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
| Fred Hutchinson Cancer Center Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.